Risk factor
Very high price volatility
Profitability factor
Very strong margins and returns
About
Shukra Pharmaceuticals Limited is a prominent company engaged in the manufacturing and global distribution of pharmaceutical products. Their comprehensive product line addresses a broad spectrum of medical conditions, encompassing anti-infective medications (such as antibiotics, macrolides, quinolones, antivirals, antifungals, antimalarials, antiprotozoals, and anti-helminthics), central nervous system drugs (including sedatives, tranquilizers, antidepressants, and anti-manic agents), gastrointestinal treatments (like anti-emetics and anti-ulcer drugs), cardiovascular remedies (beta-blockers, diuretics), pain and inflammation management (analgesics, muscle relaxants, corticosteroids), anti-tuberculosis drugs, vitamin supplements, anti-allergy medications, and therapies for metabolic imbalances such as hyper- and hypoglycemia. The company was established on March 4, 1993, and its primary operations are directed from its headquarters in Ahmedabad, India.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive